Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
John Sarantopoulos(St. Boniface Hospital), R. Donald Harvey(Emory University), James M. Cleary(Brigham and Women's Hospital), George Mulligan(Takeda (Japan)), Hélène M. Faessel(Takeda (Japan)), Geoffrey I. Shapiro(Brigham and Women's Hospital), Michael D. Pickard(Peter MacCallum Cancer Centre), John Kauh(Houston Methodist Sugar Land Hospital), Glen J. Weiss(Scottsdale Research Institute (United States)), Kristine Burke(Millennium Engineering and Integration (United States)), Jeffrey W. Clark(Massachusetts General Hospital), Bruce J. Dezube(Xilio Therapeutics (United States)), Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Roger B. Cohen(University of Pennsylvania), Allison Berger(Takeda (United States))
Cited by 168
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k